Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.65 |
| ▸ | ITGAV | P06756 | 14/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230635 | 0.85 | ITGB3 (0.60) | ITGB3ITGAVITGA2B | |
| SCHEMBL6702670 | 0.81 | ITGB3 (0.68) | ITGB3ITGAVITGA2B | |
| SCHEMBL3209804 | 0.80 | ITGB3 (0.68) | ITGB3ITGAVITGA2B | |
| SCHEMBL5879524 | 0.79 | ITGB3 (1.00) | ITGB3ITGAV | |
| SCHEMBL3228383 | 0.75 | ITGAV (0.46) | ITGB3ITGAVITGA2B | |
| SCHEMBL3220068 | 0.75 | ITGAV (0.45) | ITGB3ITGAVITGA2B | |
| SCHEMBL3232755 | 0.74 | ITGB3 (0.66) | ITGB3ITGAVITGA2B | |
| SCHEMBL5879963 | 0.73 | ITGB3 (0.90) | ITGB3ITGAV | |
| SCHEMBL7705314 | 0.70 | ITGB3 (0.45) | ITGB3ITGAVITGA2BDRD3 | |
| SCHEMBL6853814 | 0.70 | ITGB3 (0.45) | ITGB3ITGAVITGA2BDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | ITGB3, ITGAL, ITGB4 | ITGB3 1/4885ITGAV 5/4885ITGA2B 11/4885 |
| US-20040077638-A1 | Novel integrin receptor antagonists | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885ITGA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.